Optimize Financial Inc Purchases Shares of 2,014 Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Optimize Financial Inc acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,014 shares of the medical equipment provider’s stock, valued at approximately $213,000.

Other hedge funds have also recently made changes to their positions in the company. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet in the 4th quarter valued at about $25,000. Kentucky Trust Co purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth approximately $39,000. OFI Invest Asset Management bought a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $40,000. SRS Capital Advisors Inc. boosted its position in shares of Zimmer Biomet by 146.9% during the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 285 shares during the last quarter. Finally, Atala Financial Inc bought a new stake in Zimmer Biomet during the fourth quarter worth $51,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Stifel Nicolaus upped their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Raymond James decreased their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $124.15.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by corporate insiders.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $102.30 on Friday. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a 50-day moving average price of $106.31 and a 200-day moving average price of $107.04. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $127.32. The firm has a market capitalization of $20.36 billion, a PE ratio of 22.99, a price-to-earnings-growth ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the business earned $2.20 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.